Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

Clinical pharmacology and therapeutics - 1 Oct 2002

Brockmöller Jürgen, Kirchheiner Julia, Schmider Jürgen, Walter Silke, Sachse Christoph, Müller-Oerlinghausen Bruno, Roots Ivar

Abstract excerpt

OBJECTIVES: The genetically polymorphic enzyme cytochrome P450 (CYP) 2D6 contributes to the biotransformation of the antipsychotic drug haloperidol. The impact of the polymorphism on haloperidol pharmacokinetics, adverse events, and efficacy was prospectively evaluated under naturalistic conditions in 172 unselected psychiatric inpatients with acute psychotic symptoms. METHODS: Serum trough levels of haloperidol...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Haloperidol

Share to Linear Models

Share to Multivariate Analysis

Share to Schizophrenia

Share to Severity of Illness Index

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 12386646
DOI: 10.1067/mcp.2002.127494

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.PMID 12386646Read ↗

Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.Semantic proximity Read ↗

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses.Semantic proximity Read ↗

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.Semantic proximity Read ↗

Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers.Semantic proximity Read ↗

Association of CYP2D6*4 Polymorphism with the Steady-State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders.Semantic proximity Read ↗

The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.Semantic proximity Read ↗

CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.Semantic proximity Read ↗

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.Semantic proximity Read ↗

Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers.Semantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.